Abstract
Increasing knowledge on cellular biology has permitted rapid changes in the treatment of metastatic melanoma. Until 2011, dacarbazine was the gold standard treatment at our disposal. In 2011 the treatment landscape changed dramatically with the approval by the FDA of ipilimumab and vemurafenib. These drugs use two new therapeutic approaches: immunomodulation and the targeting of mutated cellular pathways in tumor cells.
These two drugs, used as single agents have shown important increases in overall survival, unseen before in patients with advanced melanoma, but are limited by their toxicities and the appearance of acquired resistances.
In this article, we review new therapeutic options in pathway-targeted –with the arrival of MEK inhibitors - and immune based melanoma therapies –with the arrival of anti-PD1 and anti-PDL1- as well as new therapeutic strategies developed to overcome acquired resistance and diminish drug toxicities.
Keywords: anti-PD1, anti PDL1, BRAF inhibitors, combination therapies, dabrafenib, immune based therapies, ipilimumab, MEK inhibitors, melanoma, vemurafenib.
Anti-Cancer Agents in Medicinal Chemistry
Title:New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies
Volume: 15 Issue: 4
Author(s): F. Ranchon, A. Boespflug, C. Rioufol, V. Schwiertz, L. Thomas and S. Dalle
Affiliation:
Keywords: anti-PD1, anti PDL1, BRAF inhibitors, combination therapies, dabrafenib, immune based therapies, ipilimumab, MEK inhibitors, melanoma, vemurafenib.
Abstract: Increasing knowledge on cellular biology has permitted rapid changes in the treatment of metastatic melanoma. Until 2011, dacarbazine was the gold standard treatment at our disposal. In 2011 the treatment landscape changed dramatically with the approval by the FDA of ipilimumab and vemurafenib. These drugs use two new therapeutic approaches: immunomodulation and the targeting of mutated cellular pathways in tumor cells.
These two drugs, used as single agents have shown important increases in overall survival, unseen before in patients with advanced melanoma, but are limited by their toxicities and the appearance of acquired resistances.
In this article, we review new therapeutic options in pathway-targeted –with the arrival of MEK inhibitors - and immune based melanoma therapies –with the arrival of anti-PD1 and anti-PDL1- as well as new therapeutic strategies developed to overcome acquired resistance and diminish drug toxicities.
Export Options
About this article
Cite this article as:
Ranchon F. , Boespflug A. , Rioufol C. , Schwiertz V. , Thomas L. and Dalle S. , New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (4) . https://dx.doi.org/10.2174/1871520615666150101125028
DOI https://dx.doi.org/10.2174/1871520615666150101125028 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Tumor-Related Immunosuppression for Cancer Immunotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Meet Our Editorial Board Member:
Anti-Cancer Agents in Medicinal Chemistry Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) c-Myc: Linking Transformation and Genomic Instability
Current Molecular Medicine Modulators of Protein-Protein Interactions – Novel Approaches in Targeting Protein Kinases and Other Pharmaceutically Relevant Biomolecules
Current Topics in Medicinal Chemistry Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets Antimicrobial Agents Deriving from Indigenous Plants
Recent Patents on Food, Nutrition & Agriculture An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease
MicroRNA Application of Genomics in the Prevention, Treatment and Management of Achilles Tendinopathy and Anterior Cruciate Ligament Ruptures
Recent Patents on DNA & Gene Sequences Flavonoids with Therapeutic Potential in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets Genetic Polymorphisms and Haplotypes of Major Drug Metabolizing Enzymes in East Asians and Their Comparison with Other Ethnic Populations
Current Pharmacogenomics The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel, Targeted Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cytochrome P450-Mediated Estrogen Metabolites and Autoimmunity: Relationship and Link to Free Radicals
Current Drug Metabolism Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments
Current Drug Targets Discussion on Pharmacogenetic Interaction in G6PD Deficiency and Methods to Identify Potential Hemolytic Drugs
Cardiovascular & Hematological Disorders-Drug Targets Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Current Pharmaceutical Design Increased OPG Expression and Impaired OPG/TRAIL Ratio in the Aorta of Diabetic Rats
Medicinal Chemistry